Current measles outbreaks: Can we do better for infants at risk?

Pediatric Infectious Disease Journal

Volumn 31, Issue 7, 2012, Pages 756-758

  MacHaira, Maria ^a   Papaevangelou, Vassiliki ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MATERNAL ANTIBODY; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE;

EPIDEMIC; FRANCE; GERMANY; GESTATIONAL AGE; HUMAN; INFANCY; INFANT MORTALITY; INFECTION RISK; MEASLES; MEASLES VACCINATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; SUSCEPTIBLE POPULATION;

DISEASE OUTBREAKS; HUMANS; INFANT; MEASLES; MEASLES VACCINE; WORLD HEALTH;

EID: 84862736216     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31825ad11b     Document Type: Review

References (35)

1. WHO Measles Media Center. Fact sheet No. 286. October 2011. Available at: http://www.who.int/mediacentre/factsheets/fs286/en/. Accessed February 28, 2012.
2. Centers for Disease Control and Prevention. Progress in reducing global measles deaths, 1999-2004. MMWR. 2006;55:247-249.
3. Dannetun E, Tegnell A, Hermansson G, et al. Timeliness of MMR vaccination-influence on vaccination coverage. Vaccine. 2004;22:4228-4232. (Pubitemid 39330344)
4. De Serres G, Gay NJ, Farrington CP. Epidemiology of transmissible diseases after elimination. Am J Epidemiol. 2000;151:1039-48; discussion 1049. (Pubitemid 30489197)
5. Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine. 2007;25:6296-6304. (Pubitemid 47090234)
6. Bozzola E, Quondamcarlo A, Krzysztofiak A, et al. Re-emergence of measles in young infants. Pediatr Infect Dis J. 2011;30:271.
7. Grgic-Vitek M, Frelih T, Ucakar V, et al. Spotlight on measles 2010: a cluster of measles in a hospital setting in Slovenia, March 2010. Euro Surveill. 2010;15:pii: 19573.
8. Wichmann O, Hellenbrand W, Sagebiel D, et al. Large measles outbreak at a German public school, 2006. Pediatr Infect Dis J. 2007;26:782-786. (Pubitemid 47329847)
9. Parent du Châtelet I, Antona D, Freymuth F, et al. Spotlight on measles 2010: update on the ongoing measles outbreak in France 2008-2010. Euro Surveill. 2010;15:pii: 19656.
10. Stanescu A, Janta D, Lupulescu E, et al. Ongoing measles outbreak in Romania, 2011. Euro Surveill. 2011;16:pii:19932.
11. Marinova L, Muscat M, Mihneva Z, et al. An update on an ongoing measles outbreak in Bulgaria, April-November 2009. Euro Surveill. 2009;14:pii: 19442.
12. Gee S, Cotter S, O'Flanagan D; National Incident Management Team. Spotlight on measles 2010: measles outbreak in Ireland 2009-2010. Euro Surveill. 2010;15:pii: 19500.
13. Pervanidou D, Horefti E, Patrinos S, et al. Spotlight on measles 2010: ongoing measles outbreak in Greece, January-July 2010. Euro Surveill. 2010;15:pii: 19629.
14. Centers for Disease Control and Prevention. Measles-United States, January-May 20, 2011. MMWR. 2011;60:666-668.
15. Pabst HF, Spady DW, Marusyk RG, et al. Reduced measles immunity in infants in a well-vaccinated population. Pediatr Infect Dis J. 1992;11:525-529.
16. Jefferson T, Price D, Demicheli V, et al. European Research Program for Improved Vaccine Safety Surveillance (EUSAFEVAC) Project. Unintended events following immunization with MMR: a systematic review. Vaccine. 2003;21:3954-3960. (Pubitemid 37338223)
17. European Center of Disease Prevention and Control. MMR vaccination overview in European countries. Available at: http://ecdc.europa.eu/en/ activities/surveillance/euvac/schedules/Pages/mmr-schedule.aspx. Accessed February 28, 2012.
18. Gagneur A, Pinquier D. Letter to the editor. Spotlight on measles 2010: timely administration of the first dose of measles vaccine in the context of an ongoing measles outbreak in France. Euro Surveill. 2010;15:19689; author reply 19686.
19. Centers for Disease Control and prevention. Travellers' recommendation. Available at: http://wwwnc.cdc.gov/travel/notices/in-the-news/measles.htm. Accessed February 28, 2012.
20. Hartter HK, Oyedele OI, Dietz K, et al. Placental transfer and decay of maternally acquired antimeasles antibodies in Nigerian children. Pediatr Infect Dis J. 2000;19:635-641. (Pubitemid 30469771)
21. Martins CL, Garly ML, Balé C, et al. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. BMJ. 2008;337:a661.
22. Klinge J, Lugauer S, Korn K, et al. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age. Vaccine. 2000;18:3134-3140. (Pubitemid 30345695)
23. Glezen WP. Effect of maternal antibodies on the infant immune response. Vaccine. 2003;21:3389-3392. (Pubitemid 36792092)
24. Leuridan E, Hens N, Hutse V, et al. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ. 2010;340: c1626.
25. Leineweber B, Grote V, Schaad UB, et al. Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubella and varicella-zoster virus in preterm and full term newborns. Pediatr Infect Dis J. 2004;23:361-363. (Pubitemid 38508894)
26. Jo DS, Lee SH, Kim SY. Measles IgG titer of mothers and infants under 12 months of age in Korea. 26th Annual Meeting of the European Society of Pediatric Infectious Diseases, Graz, Austria, May 13-17, 2008 [Abstract 636].
27. Shilpi T, Sattar H, Miah MR. Determining infants' age for measles vaccination based on persistence of protective level of maternal measles antibody. Bangladesh Med Res Counc Bull. 2009;35: 101-104.
28. Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis. 2001; 184:817-826. (Pubitemid 32881086)
29. Zanetta RA, Amaku M, Azevedo RS, et al. Optimal age for vaccination against measles in the State of São Paulo, Brazil, taking into account the mother's serostatus. Vaccine. 2001;20:226-234. (Pubitemid 32905336)
30. Carson MM, Spady DW, Beeler JA, et al. Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII at 15 months of age and antibody levels at 27 months of age. Vaccine. 2005;23:3247-3255. (Pubitemid 40523117)
31. Capozzo AV, Ramírez K, Polo JM, et al. Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. J Immunol. 2006;176:5671-5681.
32. de Vries RD, Stittelaar KJ, Osterhaus AD, et al. Measles vaccination: new strategies and formulations. Expert Rev Vaccines. 2008;7:1215-1223.
33. Mossong J, Muller CP. Modelling measles re-emergence as a result of waning of immunity in vaccinated populations. Vaccine. 2003;21:4597-4603. (Pubitemid 37315781)
34. Gagneur A, Pinquier D. Early waning of maternal measles antibodies: why immunization programs should be adapted over time. Expert Rev Anti Infect Ther. 2010;8:1339-1343.
35. Steffens I, Martin R, Lopalco P. Spotlight on measles 2010: measles elimination in Europe-a new commitment to meet the goal by 2015. Euro Surveill. 2010;15:pii: 19749.